Study of 89Zr-Df-IAB22M2C PET/CT as an imaging biomarker for assessing an early response to
therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This
study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are
potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable
disease based on RECIST 1.1 are potentially eligible. Associations with progression-free
survival (PFS) and overall survival (OS) will be tested.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania